Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b elagolix study for heavy menstrual bleeding associated with uterine fibroids
2013-000082-37Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elagolix in Fibromyoma (LM) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Change in menstrual blood loss. Started Oct 2013; status: completed.
02
Drugs
elagolix
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on 2013-000082-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000082-37.